PofoliaShared via Pofolia

FOCUS The Journal of Lifelong Learning in Psychiatry· 2013

The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease

Marilyn S. Albert, Steven T. DeKosky, Dennis W. Dickson, Bruno Dubois et al.

Short summary

New diagnostic criteria for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) have been developed, including core clinical criteria and research criteria incorporating biomarkers.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Developed two sets of diagnostic criteria for MCI due to AD: core clinical and research criteria.
  • Research criteria incorporate biomarkers from imaging and cerebrospinal fluid analysis.
  • Criteria have four levels of certainty based on biomarker presence and nature.
  • Further validation and standardization of biomarker analysis for community settings are required.

AI-generated from the title and abstract; the full text is not read.

Abstract

The National Institute on Aging and the Alzheimer’s Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer’s disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings. (Reprinted with permission from Alzheimers Dement 2011;7(3):270–279)

The authors' abstract, as published at the source. FOCUS The Journal of Lifelong Learning in Psychiatry, 2013 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Psychiatry and Mental health

Psychiatry and Mental healthMedicine